CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni Sells 19,582 Shares

CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni sold 19,582 shares of the company’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $59.91, for a total transaction of $1,173,157.62. Following the completion of the transaction, the chief executive officer now owns 208,122 shares of the company’s stock, valued at approximately $12,468,589.02. The sale was disclosed in a filing with the SEC, which is available at this link.

Samarth Kulkarni also recently made the following trade(s):

• On Friday, March 15th, Samarth Kulkarni sold 20,000 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $72.48, for a total transaction of $1,449,600.00.
• On Monday, March 11th, Samarth Kulkarni sold 9,802 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $78.26, for a total transaction of $767,104.52.
• On Tuesday, February 20th, Samarth Kulkarni sold 6,370 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $79.67, for a total transaction of $507,497.90.
• On Thursday, February 15th, Samarth Kulkarni sold 20,000 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $80.36, for a total transaction of $1,607,200.00.
• On Monday, January 29th, Samarth Kulkarni sold 50,000 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $60.51, for a total transaction of $3,025,500.00.

CRISPR Therapeutics Trading Down 4.1 %

Shares of CRISPR Therapeutics stock traded down $2.40 during mid-day trading on Wednesday, hitting $55.56. 1,397,646 shares of the stock were exchanged, compared to its average volume of 1,847,458. CRISPR Therapeutics AG has a twelve month low of $37.55 and a twelve month high of $91.10. The stock has a market capitalization of $4.72 billion, a price-to-earnings ratio of -28.88 and a beta of 1.76. The company has a 50-day simple moving average of $73.89 and a 200 day simple moving average of $63.30.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Wednesday, February 21st. The company reported $1.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.15 by $0.95. The firm had revenue of $201.20 million for the quarter, compared to analyst estimates of $148.72 million. During the same period in the prior year, the business earned ($1.41) earnings per share. CRISPR Therapeutics’s revenue for the quarter was up 3253.3% on a year-over-year basis. Equities research analysts forecast that CRISPR Therapeutics AG will post -6.24 earnings per share for the current fiscal year.

Hedge Funds Weigh In On CRISPR Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Signaturefd LLC boosted its position in CRISPR Therapeutics by 12.5% in the 3rd quarter. Signaturefd LLC now owns 2,124 shares of the company’s stock valued at $96,000 after buying an additional 236 shares during the last quarter. Itau Unibanco Holding S.A. boosted its position in CRISPR Therapeutics by 10.8% in the 3rd quarter. Itau Unibanco Holding S.A. now owns 2,521 shares of the company’s stock valued at $114,000 after buying an additional 245 shares during the last quarter. Spire Wealth Management boosted its position in CRISPR Therapeutics by 32.7% in the 3rd quarter. Spire Wealth Management now owns 1,052 shares of the company’s stock valued at $48,000 after buying an additional 259 shares during the last quarter. CWM LLC boosted its position in CRISPR Therapeutics by 80.7% in the 3rd quarter. CWM LLC now owns 582 shares of the company’s stock valued at $26,000 after buying an additional 260 shares during the last quarter. Finally, Voya Investment Management LLC lifted its position in shares of CRISPR Therapeutics by 1.2% during the fourth quarter. Voya Investment Management LLC now owns 22,129 shares of the company’s stock worth $900,000 after purchasing an additional 269 shares during the last quarter. 69.20% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Chardan Capital upped their price target on shares of CRISPR Therapeutics from $110.00 to $112.00 and gave the company a “buy” rating in a research report on Thursday, February 22nd. Wells Fargo & Company upped their price objective on shares of CRISPR Therapeutics from $55.00 to $70.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 22nd. Mizuho upped their price objective on shares of CRISPR Therapeutics from $82.00 to $99.00 and gave the stock a “buy” rating in a research report on Wednesday, March 6th. Wolfe Research started coverage on shares of CRISPR Therapeutics in a research report on Thursday, February 15th. They set a “peer perform” rating for the company. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $90.00 price target on shares of CRISPR Therapeutics in a report on Thursday, April 11th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $74.93.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.